Detailed Information
Cited 2 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
An open label, randomized phase III trial evaluating the treatment (tx) effects of panitumumab (pmab) plus best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
- Authors
- Kim, TW[Kim, Tae Won]; Elme, A[Elme, Anneli]; Kusic, Z[Kusic, Zvonko]; Park, JO[Park, Joon Oh]; Udrea, AA[Udrea, Anghel Adrian]; Kim, SY[Kim, Sun Young]; Ahn, JB[Ahn, Joong Bae]; Valencia, RV[Valencia, Ricardo Villalobos]; Srinivasan, K[Srinivasan, Krishnan]; Bilic, A[Bilic, Ante]; Manojlovic, N[Manojlovic, Nebojsa]; Dong, J[Dong, Jun]; Guan, XS[Guan, Xuesong]; Lofton-Day, C[Lofton-Day, Catherine]; Jung, AS[Jung, A. Scott]; Vrdoljak, E[Vrdoljak, Eduard]
- Issue Date
- 1-Feb-2016
- Publisher
- AMER SOC CLINICAL ONCOLOGY
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.34, no.4
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 34
- Number
- 4
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.